Patents by Inventor Yiping He
Yiping He has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240132603Abstract: Involved is an isolated antigen binding protein, being capable of binding CCR8 derived from a primate animal. Further involved are a pharmaceutical composition comprising the antigen binding protein, and an application of the antigen binding protein and/or the pharmaceutical composition in the prevention and/or treatment of a tumor or a cancer.Type: ApplicationFiled: August 26, 2021Publication date: April 25, 2024Applicant: HARBOUR BIOMED US, INC.Inventors: Shuang LU, Yongqiang WANG, Xin GAN, Fei CHEN, Jinqiu HE, Xiaohui SHAO, Shaoping HU, Chuchu ZHAO, Jiuqiao ZHAO, Yiping RONG
-
Patent number: 11952400Abstract: Provided are a bovine rotavirus fusion protein and calf diarrhea multivalent vaccine. The bovine rotavirus fusion protein contains a VP6 fragment, wherein the VP6 fragment contains an amino acid sequence as represented by SEQ ID NO. 4, and at least one loop region of the following (a)˜(c) is substituted with an antigenic epitope derived from bovine coronavirus and/or an antigenic epitope derived from E. coli: (a) amino acid residues of sites 168-177; with an amino acid sequence as represented by SEQ ID NO. 1; (b) amino acid residues of sites 194-205; with an amino acid sequence as represented by SEQ ID NO. 2; and (a) amino acid residues of sites 296-316, with an amino acid sequence as represented by SEQ ID NO. 3, The bovine rotavirus fusion protein contains a plurality of antigenic epitopes, and can enable a host to generate a plurality of antibodies after immunizing the host.Type: GrantFiled: April 16, 2021Date of Patent: April 9, 2024Assignee: TECON BIOPHARMACEUTICAL CO., LTD.Inventors: Sun He, Yiping Pan, Guoqing Zhang, Pengxian Yan, Na Xi, Miaomiao Guo, Shengdong Xiao, Tianzeng Li, Rui Han, Yumeng Wang, Jiubin Du, Pei Zheng, Jian Cao
-
Patent number: 10633711Abstract: Methods that rapidly, sensitively, and specifically detect mutations in IDH1/2 and the TERT promoter employ amplification of particular portions of the genes that experience frequent and exquisitely localized mutations. The ability to distinguish between sequences that differ only by one nucleotide and which may be present in very low ratios is essential for such an assay.Type: GrantFiled: August 24, 2015Date of Patent: April 28, 2020Assignee: Duke UniversityInventors: Hai Yan, Yiping He, Rui Yang, Bill H. Diplas, Landon Hansen, Darell Bigner
-
Publication number: 20170247765Abstract: Methods that rapidly, sensitively, and specifically detect mutations in IDH1/2 and the TERT promoter employ amplification of particular portions of the genes that experience frequent and exquisitely localized mutations. The ability to distinguish between sequences that differ only by one nucleotide and which may be present in very low ratios is essential for such an assay.Type: ApplicationFiled: August 24, 2015Publication date: August 31, 2017Applicant: Duke UniversityInventors: Hai Yan, Yiping He, Rui Yang, Bill H. Diplas, Landon Hansen, Darell Bigner
-
Patent number: 9637779Abstract: Transcription in mammalian cells can be assessed at a genome-wide level, but it has been difficult to reliably determine whether individual transcripts are derived from the Plus- or Minus-strands of chromosomes. This distinction can be critical for understanding the relationship between known transcripts (sense) and the complementary antisense transcripts that may regulate them. Here we describe a technique that can be used to (i) identify the DNA strand of origin for any particular RNA transcript and (ii) quantify the number of sense and antisense transcripts from expressed genes at a global level. We examined five different human cell types and in each case found evidence for antisense transcripts in 2900 to 6400 human genes. The distribution of antisense transcripts was distinct from that of sense transcripts, was non-random across the genome, and differed among cell types.Type: GrantFiled: December 2, 2009Date of Patent: May 2, 2017Assignee: The Johns Hopkins UniversityInventors: Bert Vogelstein, Kenneth W. Kinzler, Yiping He, Victor Velculescu, Nickolas Papadopoulos
-
Publication number: 20120202883Abstract: Point mutations of the NADP+-dependent isocitrate dehydrogenases (IDH1 and IDH2) occur early in the pathogenesis of gliomas. When mutated, IDH1 and IDH2 gain the ability to produce the metabolite (R)-2-hydroxyglutarate (2HG), but the downstream effects of mutant IDH1 and IDH2 proteins or of 2HG on cellular metabolism are unknown. Here, we profiled >200 metabolites in human oligodendroglioma cell line (HOG) cells to determine the effects of expression of IDH1 and IDH2 mutants. Levels of amino acids, glutathione metabolites, choline derivatives, and tricarboxylic acid (TCA) cycle intermediates were altered in both mutant IDH1- and IDH2-expressing cells. These changes were similar to those identified after treatment of the cells with 2HG. Remarkably, N-acetyl-aspartyl-glutamate (NAAG), a common dipeptide in brain, was 50-fold reduced in cells expressing IDH1 mutants and 8.3-fold reduced in cells expressing IDH2 mutants.Type: ApplicationFiled: January 20, 2012Publication date: August 9, 2012Applicant: DUKE UNIVERSITYInventors: Yan Hai, Darell Bigner, Yiping He, Genglin Jin, Zachary Reitman
-
Publication number: 20120009573Abstract: Transcription in mammalian cells can be assessed at a genome-wide level, but it has been difficult to reliably determine whether individual transcripts are derived from the Plus- or Minus-strands of chromosomes. This distinction can be critical for understanding the relationship between known transcripts (sense) and the complementary antisense transcripts that may regulate them. Here we describe a technique that can be used to (i) identify the DNA strand of origin for any particular RNA transcript and (ii) quantify the number of sense and antisense transcripts from expressed genes at a global level. We examined five different human cell types and in each case found evidence for antisense transcripts in 2900 to 6400 human genes. The distribution of antisense transcripts was distinct from that of sense transcripts, was non-random across the genome, and differed among cell types.Type: ApplicationFiled: December 2, 2009Publication date: January 12, 2012Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Bert Vogelstein, Kenneth W. Kinzler, Yiping He, Victor Velculescu, Nickolas Papadopoulos
-
Publication number: 20110014214Abstract: Provided are methods for the diagnosis and treatment of acute myelogenous leukemia. In particular, the present invention relates to the use of Trib2 polynucleotides and polypeptides for the diagnosis and treatment of acute myelogenous leukemia (AML) by assessing myeloid cells of a patient, or malignancies associated with Trib2, C/EBP?p30 or C/EBP?p42, such as AML or lung cancer, by assessing hematopoietic stem cells of the patient.Type: ApplicationFiled: January 19, 2007Publication date: January 20, 2011Inventors: Warren S. Pear, Karen Keeshan, Yiping He
-
Patent number: 7586970Abstract: A second-order multi-mode partial distributed feedback (p-DFB) laser having increased electrical-to-optical power conversion efficiency, stabilized wavelength and narrowed emission linewidth. The laser includes an abbreviated grating housed in the laser cavity that is separated from both the front-end and the back-end of the laser facets.Type: GrantFiled: July 13, 2007Date of Patent: September 8, 2009Assignee: Alfalight, Inc.Inventors: Manoj Kanskar, Yiping He, Steven H. Macomber
-
Publication number: 20080212635Abstract: The invention provides a grating for a distributed feedback laser having decreased diffraction loss with reduced +/?1 order diffraction and scattering loss resulting from the reduced imperfections in the grating fabrication. In various embodiments, the grating has a low duty cycle wherein the ratio of the length of the low-index portion ‘a’ to the length of the pitch of the grating ‘b’ is less than 0.5. Further, in some preferred embodiments, the invention includes a laser, the laser comprising a distributed feedback laser wherein the laser includes a grating having less diffraction and less scattering loss. In various exemplary embodiments, the grating is further a partial grating, thereby providing increased efficiency resulting from a decrease in first-order diffraction loss due to the grating being separated from the front and rear facets and in some exemplary embodiments being situated at the area of lowest electric filed.Type: ApplicationFiled: February 25, 2008Publication date: September 4, 2008Applicant: Alfalight, Inc.Inventors: Manoj Kanskar, Yiping He, Steve H. Macomber
-
Publication number: 20080205476Abstract: A second-order multi-mode partial distributed feedback (p-DFB) laser having increased electrical-to-optical power conversion efficiency, stabilized wavelength and narrowed emission linewidth. The laser includes an abbreviated grating housed in the laser cavity that is separated from both the front-end and the back-end of the laser facets.Type: ApplicationFiled: July 13, 2007Publication date: August 28, 2008Inventors: Manoj KANSKAR, Yiping HE, Steven H. MACOMBER
-
Publication number: 20060240505Abstract: A method of determining the cellular or genetic target of an antimicrobial compound includes cloning of a bacterial gene into an expression vector with an inducible promoter and determining whether increasing expression of the cloned gene in the cell will result in resistance to an antimicrobial compound. Also, the method can include incorporation of every gene of a bacterial strain into expression vectors having an inducible promoter, induction, treating with an antimicrobial compound, isolating the gene clone that confers cells resistant to the compound, and determining the identity of the resistant gene by various methods including DNA microarrays and gene sequencing.Type: ApplicationFiled: June 28, 2006Publication date: October 26, 2006Inventors: Frank Fan, Yiping He, Jianzhong Huang, Xinhe Jiang, Damien McDevitt, Martin Rosenberg, Annemarie St. John
-
Publication number: 20040029201Abstract: A method of determining the cellular or genetic target of an antimicrobial compound includes cloning of a bacterial gene into an expression vector with an inducible promoter and determining whether increasing expression of the cloned gene in the cell will result in resistance to an antimicrobial compound. Also, the method can include incorporation of every gene of a bacterial strain into expression vectors having an inducible promoter, induction, treating with an antimicrobial compound, isolating the gene clone that confers cells resistant to the compound, and determining the identity of the resistant gene by various methods including DNA microarrays and gene sequencing.Type: ApplicationFiled: July 11, 2003Publication date: February 12, 2004Applicant: SmithKline Beecham Corporation and SmithKline Beecham p.I.c.Inventors: Frank Fan, Yiping He, Jianzhong Huang, Xinhe Jiang, Damien McDevitt, Martin Rosenberg, Annemarie C. St, John
-
Publication number: 20030181380Abstract: Provided are methods for manipulating aspects of lymphopoiesis by modulating and controlling Notch signaling, thereby providing treatment for diseases of the immune system. Accordingly, there are provided methods for selectively modulating T cell fate commitment of a common lymphoid progenitor at the expense of B cell fate commitment, and in the converse for selectively modulating B cell fate commitment of a common lymphoid progenitor at the expense of T cell fate commitment. Also provided are methods for treating patients suffering from a disease or disorder of T cell origin, or conversely of B cell origin. Further provided are methods for selectively killing B cells in a committed population of B cells, such as in a patient suffering from B cell leukemia or lymphoma; as well as methods for selectively killing T cells in a committed population of T cells such as in a patient suffering from diseases of T cell origin.Type: ApplicationFiled: March 10, 2003Publication date: September 25, 2003Inventors: Warren S. Pear, David Allman, Yiping He, David J. Izon, Jon C. Aster
-
Publication number: 20020086310Abstract: A method of determining the cellular or genetic target of an antimicrobial compound includes cloning of a bacterial gene into an expression vector with an inducible promoter and determining whether increasing expression of the cloned gene in the cell will result in resistance to an antimicrobial compound. Also, the method can include incorporation of every gene of a bacterial strain into expression vectors having an inducible promoter, induction, treating with an antimicrobial compound, isolating the gene clone that confers cells resistant to the compound, and determining the identity of the resistant gene by various methods including DNA microarrays and gene sequencing.Type: ApplicationFiled: August 30, 2001Publication date: July 4, 2002Inventors: Frank Fan, Yiping He, Jianzhong Huang, Xinhe Jiang, Damien McDevitt, Martin Rosenberg, Annemarie C. St. John